Perioperative Troponin I and NT Pro-BNP in Lung Resection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

475 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-19

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After lung resection, troponin elevation may be regulated by mechanisms other than myocardial ischemia. Perioperative natriuretic peptides measurement may help identify changes in ventricular function during thoracic surgery. Integrating both cardiac biomarkers may improve the predictive value for cardiovascular complications after lung resection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Perioperative Cardiac Troponin Levels in Healthy Adults

NCT02394288

Extremity Orthopedic Surgery

COMPLETED

Is There a Correlation of Natriuretic Propeptide Type B With an Intraoperative Low Cardiac Output?

NCT00586027

Cardiac Surgery Low Cardiac Output Natriuretic Peptide B

COMPLETED

Preoperative BNP as Biomarker of Postoperative Cardiovascular Complications

NCT02570607

Postoperative Cardiovascular Complications

COMPLETED

Evaluation of the Brain Natriuretic Peptide as a Predictor of Morbidity and Mortality in Cardiac Surgery

NCT00699673

Coronary Artery Disease Valvular Disease

UNKNOWN

Preoperative BNP: Epidemiological Patterns, Management Strategies and Cost Analysis of Care

NCT04077294

Myocardial Infarction Postoperative Myocardial Injury Death, Cardiac

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives: To evaluate the incidence and magnitude of perioperative N-terminal pro brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin I (Tn I) elevation in patients undergoing pulmonary resection and its predictive value for cardiovascular complications. Methodology: Prospective, multicenter, observational cohort study in patients \>45 years undergoing elective thoracic surgery for lung resection. Cardiac biomarkers Tn I and NT-proBNP will be measured preoperatively and at postoperative days 1 and 2. Risk score for major cardiovascular postoperative complications will be calculated depending of both biomarkers perioperative changes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Ischemia Thoracic Cancer Complication,Postoperative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

serum high-sensitivity Troponin I (TnI) and NT-Pro-Brain Natriuretic Peptide (NT-proBNP)

Both biomarkers will be determined in each patient preoperatively and at postoperative day 1 and day 2.Measurements will not necessarily be taken independently of other measurements, meaning that the addition of the biomarker could be included in routine pre or postoperative day-1 and day 2 blood tests.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥45 years old
* Patients undergoing elective surgery for lung resection

Exclusion Criteria

* Patients undergoing urgent, emergent, or nonthoracic surgery
* Patients or family did not consent to participate
* Presence of symptoms related with infection or sepsis
* Patients with a documented history of severe heart failure and/or ejection fraction lower than 30%

Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No